A Urolithin A Trial Missed Its Main Goal. The Press Release Led With Something Else
Every clinical trial names its main question before it starts. That rule exists so nobody can run a study, look at twenty measurements and report whichever one moved. This small urolithin A trial is a neat example of why the rule matters.
- A randomized trial published in JAMA Network Open on October 9, 2026 gave 50 adults aged 40 to 64 with obesity 1,000 mg of urolithin A a day or placebo for 4 weeks.
- Its main outcome, a measure of blood vessel function called flow mediated dilation, did not change significantly: 1.3 percent on urolithin A versus 0.3 percent on placebo, P = .33.
- Brain oxygenation in one region rose during a thinking task, and that became the headline in later coverage. Memory and task performance did not improve.
What was tested
Urolithin A is a compound the gut makes from polyphenols in foods such as pomegranate, and it is sold as a supplement for mitochondrial and muscle health. In this trial, 50 adults aged 40 to 64 with obesity were randomized to 1,000 mg of urolithin A a day or a placebo for four weeks. Forty three completed it.

A pomegranate. The gut makes urolithin A from polyphenols in foods like this one.
איתן פרמן
Illustrative. The trial used a 1,000 mg supplement, not pomegranate.
The registered primary outcome was flow mediated dilation, which measures how well an artery widens when blood flow increases, a common marker of blood vessel health.
What happened to the main question
Flow mediated dilation rose by 1.3 percent on urolithin A and 0.3 percent on placebo. The difference was not statistically significant: the estimate was 1.74 with a confidence interval running from minus 1.33 to 4.81, and P was .33. On its own main question, the trial found no clear effect.
Primary: blood vessel function
1.3 percent versus 0.3 percent, P = .33.
Secondary: brain oxygenation
One region, during a task.
Memory and task scores
No improvement.
50 adults aged 40 to 64 with obesity, 1,000 mg a day for 4 weeks, 43 completed.
What got the attention
Among the secondary measures, brain oxygenation in the left dorsolateral prefrontal cortex, a region involved in planning and attention, rose during a cognitive task, and that held up after the researchers corrected for multiple comparisons. A university press release a month later led with this brain blood flow finding, while also reporting that blood vessel function and memory test results did not improve significantly.
it is not the same as a benefit you would notice
The trial also measured whether people actually thought better. Memory and task scores did not improve. A change in blood oxygenation during a task is interesting physiology, but it is not the same as a benefit you would notice.
Honest caveat
Four weeks and 50 people is very small and very short for a vascular outcome, so a real but modest effect could have been missed. About three quarters of participants were women, and about one in five was taking a GLP-1 drug, which may have affected results. The secondary findings are worth testing again, not worth acting on.
What this means for you
If you take urolithin A for heart or blood vessel health, this trial does not support that use, though it is too small to rule it out. If you take it for focus or memory, the brain finding is a hint for future research, not evidence of a benefit.
The broader habit worth keeping: when a supplement study reaches you through a press release, look for the primary outcome first. If the headline is about something else, that tells you something.
Primary sources
Common questions
Did urolithin A improve blood vessel function?
Not significantly. Flow mediated dilation rose 1.3 percent on urolithin A and 0.3 percent on placebo, with P = .33, so the trial's main outcome was not met.
Did it improve memory?
No. Brain oxygenation in one region rose during a task, but memory and task scores did not improve.
Why does the primary outcome matter?
It is the question the trial was designed and powered to answer. Secondary findings are useful for future studies, but a trial that measures many things will find some changes by chance.
Stay Curious.
Better health isn't found in a single article. It's built through curiosity, evidence, and small discoveries over time. Join thousands exploring longevity, gut health, recovery, nutrition, and the tools that truly make a difference.